Posted in | News | Nanomedicine

NanoViricides Advances its Drug Product Line Through IND Submission

A developer of nanomaterials for antiviral therapy, NanoViricides has stated that the company is financially stable and equipped with resources to enhance its drug product line by its first IND submission to the FDA.

Recently, NanoViricides had reported that the post-infection treatment performed using three different kinds of FluCide drug agents resulted in the survival of animals during the study period. The drugs enabled more than 95% reduction in necrosis and lung inflammation as well as more than 1000-fold decrease of viral load in the animals’ lungs that were infected with fatal dosage of influenza virus. Thus, the company hopes that the FluCide program is used for further development with respect to IND submission.

Also, the company has declared that its present HIVCide drug candidate was equivalent to the HAART triple drug cocktail of HIV-resistant drugs in a typical humanized mouse model known as SCID hu-Thy/Liv mouse model. This study was performed to find an anti-HIV nanoviricide ligand that is better than previously used ligands as well as to validate past study results.

At present, NanoViricides includes five key candidates in its drug pipeline such as DengueCide, HerpiCide, HIVCide, FluCide, and a wide-spectrum of nanoviricide eye drops for treating eyes’ viral infections. These programs are solely based on NanoViricides’ technology that allows targeting a specific kind of virus. Further, the company is working on other research and development programs including its unique accurate drug in field (ADIF) technologies which aim to attack new viruses, irrespective of its source either natural such as SARS or man-made, before causing a pandemic, as well as wide-spectrum nanoviricides against several neglected tropical diseases.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 12). NanoViricides Advances its Drug Product Line Through IND Submission. AZoNano. Retrieved on April 24, 2024 from

  • MLA

    NanoViricides, Inc. "NanoViricides Advances its Drug Product Line Through IND Submission". AZoNano. 24 April 2024. <>.

  • Chicago

    NanoViricides, Inc. "NanoViricides Advances its Drug Product Line Through IND Submission". AZoNano. (accessed April 24, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides Advances its Drug Product Line Through IND Submission. AZoNano, viewed 24 April 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.